Chandana Taila Uttarabasti for Prostate Cancer: A Clinical Study

A RANDOMISED CONTROL CLINICAL STUDY TO EVALUATE THE EFFICACY OF CHANDANA TAILA UTTARBASTI IN MANAGEMENT OF PROSTATE CANCER - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104012

Enrollment

Registered

2026-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C61- Malignant neoplasm of prostate

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males aged between 40 and 75 years 2. Diagnosed with prostate cancer (Stage I or II or III) based on clinical and radiological findings. 3. Willing to undergo Uttarbasti treatment and provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Metastatic stage (Stage IV) prostate cancer 2. Patients with uncontrolled diabetes, hypertension, or serious systemic illnesses 3. Active rectal disorders (fistula, fissure, piles) 4. Those undergoing surgery during the study period 5. Known allergy to ingredients of Chandana Taila

Design outcomes

Primary

Measure	Time frame
Reduction in serum PSA levels from baseline to completion of treatment.Timepoint: 10 WEEKS	—

Secondary

Measure	Time frame
Improvement in urinary and quality-of-life parameters assessed by EPIC questionnaire; radiological changes in prostate; safety and tolerability of Chandana Taila Uttarabasti.Timepoint: 10 WEEKS	—

Countries

India

Contacts

Public ContactDr Hemant Toshikhane

Parul Institute of Ayurved

hemant.toshikhane@paruluniversity.ac.in8469496525

Outcome results